Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Other Gross PP&E Adjustments (2020 - 2025)

Ovid Therapeutics' Other Gross PP&E Adjustments history spans 6 years, with the latest figure at -$16.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 2.41% year-over-year to -$16.4 million; the TTM value through Dec 2025 reached -$16.4 million, up 2.41%, while the annual FY2025 figure was -$16.4 million, 2.41% up from the prior year.
  • Other Gross PP&E Adjustments reached -$16.4 million in Q4 2025 per OVID's latest filing, down from -$10.4 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$1.2 million in Q3 2021 to a low of -$19.7 million in Q4 2023.
  • Average Other Gross PP&E Adjustments over 5 years is -$12.2 million, with a median of -$12.6 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 44.06% in 2021, then plummeted 1187.73% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$4.7 million in 2021, then tumbled by 307.44% to -$19.0 million in 2022, then decreased by 3.57% to -$19.7 million in 2023, then rose by 14.65% to -$16.8 million in 2024, then grew by 2.41% to -$16.4 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Other Gross PP&E Adjustments are -$16.4 million (Q4 2025), -$10.4 million (Q3 2025), and -$10.7 million (Q2 2025).